Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) just unveiled an announcement.
JW (Cayman) Therapeutics Co. Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board comprises non-executive and independent non-executive directors, with specific members serving on various committees, such as the Audit, Remuneration, Nomination, and Business Development and Strategy Committees. This announcement is significant as it outlines the governance structure and strategic oversight within the company, potentially impacting its operational and strategic direction.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development of innovative cell-based therapies. The company operates in the healthcare industry, providing advanced therapeutic solutions aimed at treating various diseases.
Average Trading Volume: 2,092,405
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.29B
For a thorough assessment of 2126 stock, go to TipRanks’ Stock Analysis page.